Esperion to Participate in Jefferies Global Healthcare Conference - London

Core Insights - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [2] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated LDL-C levels [2] - Esperion is advancing its next-generation program targeting ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [2] Company Developments - Esperion will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 8:00 a.m. GMT [1] - The company continues to evolve through commercial execution, international partnerships, and advancements in its pre-clinical pipeline [3] Contact Information - Investor relations contact: Alina Venezia, email: investorrelations@esperion.com, phone: (734) 887-3903 [4] - Media contact: Tiffany Aldrich, email: corporateteam@esperion.com, phone: (616) 443-8438 [4]